AI assistant
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021
Aug 6, 2021
29977_dirs_2021-08-06_f4f010a9-36f8-43bc-8362-36ce95704b2d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-05
Reporting Person: YANCOPOULOS GEORGE (Director, President and Chief Scientific)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-05 | Common Stock | S | 50000 | $600.06 | Disposed | 937483 | Direct |
| 2021-06-24 | Common Stock | G | 211585 | $0.0 | Acquired | 213693 | Indirect |
| 2021-06-24 | Common Stock | G | 211585 | $0.0 | Disposed | 0 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5848 | Indirect |
Footnotes
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2: Represents volume-weighted average price of sales of 50,000 shares of Company stock on August 5, 2021 at prices ranging from $600.00 to $600.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price.
F3: As investment trustee of trusts for the benefit of the reporting person's children.